• LAST PRICE
    3.0200
  • TODAY'S CHANGE (%)
    Trending Down-0.0900 (-2.8939%)
  • Bid / Lots
    2.7400/ 51
  • Ask / Lots
    3.6900/ 1
  • Open / Previous Close
    3.0400 / 3.1100
  • Day Range
    Low 2.9500
    High 3.0900
  • 52 Week Range
    Low 1.8200
    High 8.0000
  • Volume
    176,501
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 3.11
TimeVolumePSTX
09:32 ET48833.05
09:34 ET3903.03
09:36 ET14003.05
09:38 ET1003.06
09:41 ET1003.0625
09:43 ET5003.0617
09:45 ET9803.06
09:50 ET11003.02
09:54 ET6003.03
09:59 ET70523.01
10:01 ET8003.015
10:03 ET3003.025
10:06 ET26083.025
10:08 ET3003.02
10:10 ET1003
10:15 ET2003.01
10:17 ET46842.98
10:19 ET4002.95
10:21 ET1002.95
10:26 ET1852.9699
10:28 ET5882.98
10:30 ET11002.98
10:32 ET25412.9813
10:35 ET1002.99
10:42 ET3002.99
10:46 ET1002.985
10:48 ET15003.005
10:50 ET1003
10:51 ET3002.99
10:53 ET6003
10:55 ET7303.02
10:57 ET2003.03
11:00 ET9003.0225
11:02 ET2623
11:04 ET49323.015
11:06 ET7003.0225
11:08 ET3003.04
11:09 ET19053.03
11:13 ET3003.025
11:15 ET2003.02
11:18 ET2673.015
11:20 ET10333.02
11:24 ET1003.03
11:26 ET5003.04
11:27 ET1003.04
11:31 ET2003.03
11:36 ET1003.03
11:38 ET3003.025
11:42 ET24933.05
11:45 ET8823.04
11:47 ET36003.05
11:49 ET1003.03
11:54 ET31003.05
11:56 ET6003.05
11:58 ET1003.05
12:00 ET2003.055
12:02 ET3003.07
12:03 ET1003.06
12:05 ET6003.06
12:07 ET22053.04
12:09 ET2003.04
12:12 ET1003.04
12:16 ET43423.045
12:18 ET8003.04
12:20 ET1003.0328
12:25 ET1003.03
12:30 ET34843.04
12:36 ET11003.05
12:38 ET5003.05
12:39 ET2003.05
12:45 ET13493.06
12:50 ET1003.06
12:57 ET1643.07
01:12 ET1003.07
01:17 ET5003.075
01:19 ET4483.085
01:21 ET21003.07
01:24 ET4803.065
01:28 ET7003.07
01:30 ET2003.06
01:32 ET1003.05
01:33 ET6003.05
01:44 ET5023.055
01:46 ET6003.06
01:50 ET1003.05
01:51 ET1003.07
01:53 ET2003.06
01:57 ET5713.06
02:08 ET6523.055
02:09 ET4003.05
02:11 ET2003.0568
02:13 ET4503.04
02:15 ET4003.03
02:22 ET8843.03
02:24 ET4003.03
02:26 ET6443.03
02:29 ET2003.03
02:36 ET7003.03
02:38 ET1003.01
02:42 ET1003.01
02:44 ET1003.01
02:45 ET7003.01
02:49 ET1003.005
02:51 ET12003
02:56 ET2003
02:58 ET19822.98
03:00 ET8082.98
03:02 ET13002.9899
03:03 ET12012.99
03:05 ET3003
03:09 ET9513
03:12 ET1003.01
03:14 ET10712.99
03:18 ET1003
03:20 ET1003
03:27 ET2003
03:30 ET5513.01
03:32 ET1003.01
03:38 ET5003.01
03:41 ET22043.0186
03:43 ET32433.02
03:45 ET8003.02
03:50 ET52003
03:52 ET73452.995
03:56 ET12122.995
03:57 ET40403
03:59 ET110883.02
Data delayed at least 15 minutes.
0 New Today
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesPSTX
Poseida Therapeutics Inc
259.0M
-1.3x
---
United StatesCNCE
Concert Pharmaceuticals Inc
292.9M
-1.8x
---
United StatesFDMT
4D Molecular Therapeutics Inc
260.3M
-2.4x
---
United StatesAVEO
Aveo Pharmaceuticals Inc
268.3M
-7.4x
---
United StatesAFMD
Affimed NV
291.8M
-3.5x
---
United StatesTNGX
Tango Therapeutics Inc
301.1M
-3.1x
---
As of 2022-09-25

Company Information

Poseida Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which utilizes its genetic engineering platform technologies to create cell and gene therapeutics. The Company's platforms include ournon-viral piggyBac DNA Delivery System, Cas-CLOVER Site-specific Gene Editing System and nanoparticle- and AAV-based gene delivery technologies. Its advanced product candidate, P-PSMA-101, is being developed for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC), in a Phase I trial. Its first two fully allogeneic CAR-T product candidates include P-BCMA-ALLO1 and P-MUC1C-ALLO1, both are in Phase I trial. P-BCMA-ALLO1 is developed for patients with relapsed/refractory multiple myeloma. P-MUC1C-ALLO1 is being developed to treat a range of solid tumors, including breast, ovarian and other epithelial-derived cancers. In addition, the Company has several additional allogeneic programs advancing toward anticipated IND filings, including P-CD19CD20-ALLO1.

Contact Information

Headquarters
9390 TOWNE CENTRE DRIVE, SUITE 200SAN DIEGO, CA, United States 92121
Phone
858-779-3100
Fax
302-636-5454

Executives

Executive Chairman of the Board
Eric Ostertag
President, Chief Executive Officer, Director
Mark Gergen
Chief Financial Officer
Johanna Mylet
President - Gene Therapy
Brent Warner
Chief People and Administrative Officer
Kristin Martin

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$259.0M
Revenue (TTM)
$35.4M
Shares Outstanding
85.8M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
---
EPS
$-2.27
Book Value
$2.50
P/E Ratio
-1.3x
Price/Sales (TTM)
7.3
Price/Cash Flow (TTM)
---
Operating Margin
-390.34%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.